Lifeboat Foundation

With the demise of Roche’s gantenerumab in November 2022, the Alzheimer’s disease space became a two-horse race between Eisai and Biogen’s Leqembi (lecanemab) and Eli Lilly’s donanemab. One, Leqembi, received full FDA approval in July; the other, donanemab, is widely expected to secure the agency’s approval before the end of 2023.

With a potential combined market value of $30 billion, BioSpace takes a deep dive into the Phase III data supporting Eisai and Biogen’s Leqembi and Eli Lilly’s investigational donanemab.